Disclosures. Patient 1. Goals/Format 12/7/17. Antiretroviral Therapy Management:
|
|
- Edwin Thomas
- 6 years ago
- Views:
Transcription
1 Disclosures Antiretroviral Therapy Management: Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 8, 2017 Brad Hare, MD, 1 Annie Luetkemeyer, MD 2 Susa Coffey, MD, 2 Vivek Jain, MD 2 1 Kaiser Permanente, San Francisco Brad Hare: None Annie Luetkemeyer: Research support from ViiV Susa Coffey: None Vivek Jain: Research grant support from Gilead Sciences for work in East Africa related to methods of ART care delivery Research grant support from NIH, CDC, PEPFAR & 2 Division of HIV, Infectious Diseases & Global Medicine San Francisco General Hospital, University of California, San Francisco Goals/Format Patient 1 Explore three cases in ART management Elicit audience opinions Expert panel reflections 38 year old man, no medical history Being routinely tested for HIV every three months; last negative test 3 months ago, August 2017 In November 2017, HIV test is positive CD4=640 cells/ul, HIV-1 RNA = 31,000 c/ml HIV-1 genotype is sent, and still pending Patient expresses desire to initiate ART immediately (and you agree) 1
2 Audience Preliminary Vote Given the many options for ART, would you initiate TAF/FTC (Descovy) + dolutegravir (Tivicay)? (A) YES, I would give TAF/FTC + DTG. Case 1: Susa Coffey Yes, comfortable initiating TAF/FTC + dolutegravir (B) NO, I would recommend something else. Case 1: Starting DTG + TAF/FTC is appropriate. Pt with early HIV, CD4=640, VL=31,000; genotype is pending. Mountains of data and experience with DTG + 2 NRTIs in initial ART; preferred regimen If concern for transmitted resistance (R) How likely? How likely to impact this regimen in NEXT 2-3 WEEKS? TDR present in ~15%, NRTI mutation ~7% K65R rare, M184V ~4-5% Major INSTI mutations RARE Almost certainly has fully-active DTG and TAF, fully or perhaps partially effective FTC; this should be sufficient Menza TW et al, AIDS Case 1: Starting DTG + TAF/FTC is appropriate. Pt with early HIV, CD4=640, VL=31,000; genotype is pending. Assuming resistance to 1 NRTI, should still be effective Data for DTG + 1 fully- active NRTI Naives: DTG + 3TC: PADDLE, wk 48 VF in 1/20, no mutations ACTG 5353: wk 24 VL <50 in 90%; 89% if BL VL >100,000. VF with R in 1/120 (adherence issues) Treatment-experienced: DTG + 2NRTIs SAILING: subset on DTG + 2 NRTIs with resistance to 1-2 NRTIs-> Wk 48 NO VF if 0 or 1 fully-active NRTI (0/13) DAWNING: DTG + 2NRTIs (vs LPV/r + 2NRTIs) after VF with 1 st ART regimen->251 pts w/ 1 fully active NRTI, 84% w/ VL <50 at wk 48 (vs 73% of LPV/r); no IN or new RT mutations DAWNING Study Mean BL VL 4.21 log; >100K in 22% Cahn et al. J IAS Taiwo BO, IAS Demaest J, IAS Aboud M, et al. IAS Abstract TUAB0105LB. 2
3 Real-World Risk of Virologic Failure in Pts Starting DTG-Based vs DRV-Based ART DTG + TAF/FTC is a potent, simple, tolerable regimen Likelihood of transmitted resistance is very low, and risk of VF from transmitted resistance is even lower, esp. in next 2-3 weeks Much clinical experience from SFGH RAPID ART Patients who initiated DHHS Recommended ART from 8/13-3/17 at 8 CNICS sites (N = 5177) 1229 on DTG or DRV/r with ABC/3TC, TDF/FTC, or TAF/FTC Pts All pts ahr* for VF of DTG vs DRV (95% CI) DRV DTG 0.41 ( ) Tx-naive pts (1229) DRV DTG 0.32 ( ) Virologic failure: HIV-1 RNA > 400 c/ml at 6 mos after initiating ART. *Cox models adjusted for age, CD4+ cell count, days from last HIV-1 RNA, CNICS site, sex, HBV, HCV, HIV risk factor, and race. Case 1: Counterpoint: Brad Hare No, not comfortable initiating TAF/FTC + dolutegravir Would initiate another regimen Nance R, et al. IDWeek Abstract Modified from clinicaloptions.com Case 1 (BH) Patient diagnosed w/hiv in acute care setting, last tested negative 3 months ago, CD4=640, VL=31,000, but genotype is sent and pending do not have data. Would you start DescovyDTG or something else Transmitted drug resistance still occurs ARV Drug Class % with Major IAS-USA Mutations Most Common Mutations NRTI 8.9 A62V, M41L, M184V, K70R, D67N NNRTI 7.8 K103N, K101E, L100I, V108I, Y188C/L PI 3.2 M46I/L, V321, L90M, I84V, D30N Buchacz (CROI 2013, #615). HOPS Cohort Case 1 (BH) Patient diagnosed w/hiv in acute care setting, last tested negative 3 months ago, CD4=640, VL=31,000, but genotype is sent and pending do not have data. Would you start DescovyDTG or something else Transmitted drug resistance still occurs Clinical trials: Participants always have baseline genotypes to enter Reasonable clinical strategy: Start broad (still simple), wait for the data, and refine What s worse: 2-4 weeks of one extra drug, or a lifetime of generated resistance? 3
4 Final Audience Vote Given the many options for ART, would you initiate TAF/FTC (Descovy) + dolutegravir (Tivicay)? (A) YES, I would TAF/FTC + DTG. (B) NO, I would recommend something else. Patient 2 Audience Preliminary Vote 56 year old man, no medical co-morbidities Diagnosed with HIV in 2012; initially started TDF/FTC (Truvada) + ritonavir/darunavir and achieved virologic suppression. Switched Truvada to TAF/FTC (Descovy) in 2016; maintained RTV/DRV Continuous virologic suppression Would you recommend switching off the protease inhibitor and switching to an integrase inhibitor? Or stay with current protease inhibitor? (A) I would switch the PI to an INSTI. (B) I would continue the PI. 4
5 NO Protease inhibitors in Preferred initial ART Case 2: Annie Luetkemeyer Would switch to integrase-based regimen PI s associated with: Increase CVD (53% increase in D:A:D with DRV/r!) Dyslipidemia Metabolic derangement AND NO current single pill formulation, to boot! Ryom L, et al. CROI Abstract 128LB. Ryom L, et al. CROI Abstract 128LB. DHHS guidelines 10/17 NEAT-022: 50 yrs old or Framingham >10%, on PI/r + NRTI, suppressed x 6 months, no documented resistance/virologic failure Non-inferior to PI/r Improved lipid profile Improved Framingham score (both ATZ and DRV) Gatell TUAB1012 IAS 2017 What if preexisting resistance? GenosureArchive: Useful application SPIRAL study: 282 patients suppressed on PI/r x > 24 weeks, 40% with prior virologic failure RAL-based regimen equivalent to PI/r, virologic failure rare (1 vs. 3) DTG more potent than RAL DTG/3TC dual therapy thus far effective in several pilot switch studies and several pilot treatment initiation studies, thus: ütaf should have efficacy with DTG even if M184 and 1-2 TAMs present ütransmitted INSTI resistance still very rare. Can get an Genosure Archive if worried Martinez AIDS 2010;24:1697, DOLAM Blanco EACS 2017, Taiwo EACS 2017, Figueroa IAS 2017, ACTG 5353 Taiwo IAS
6 Genosure Archive: Cautionary tale Genosure showed RT T369 A/I/V PR L10/I, D60E, 162V, L63 S/C/T Historic genotype: RT M41L, D67N, L210W, T215Y, V106I, Y181V PR: L10I, M36I/M, M46L, I54V, L63S, I64V, V82A. Concordance of Archive with GT Singh ID Week 2016 Abstract paired samples, % concordance with historical GT was 92% for Protease Inhibitor resistance and 88% for reverse transciptase. Toma ICAAC 2015 Case 2 (BH) TAF/FTC + DRV/RTV, suppressed, and you don t have any GT info 56yo man no co morbidities, on ART x7 years, good adherence à switch off PI to integrase or stay on PI? Case 2: Counterpoint: Brad Hare If it s not broken, don t fix it Where are the data for DTG/TDF with M184V? ArchiveDNA test? Want convenience? Symtuza is on the way Would stay with PI-based regimen 6
7 Prevalence of Transmitted HIV Drug Resistance in US, Genotypic analysis of samples from newly diagnosed patients in CDC National HIV Surveillance System (N = 12,668) Cases (%) Ocfemia MC, et al. CROI Abstract 730. All cases with sequences Cases classified as recent infections Cases classified as long-standing infections 0 1 or more 1 class 2 class 3 class NNRTI NRTI PI Transmitted Drug Resistance Mutations 4.1 Pts (%) EMERALD: Switch From Boosted PI + FTC/TDF to DRV/COBI/FTC/TAF in Suppressed Pts Randomized, open-label, active-controlled phase III trial in which virologically suppressed pts continued a boosted PI + FTC/TDF regimen or switched to DRV/COBI/FTC/TAF single-tablet regimen (N = 1149) Treatment difference: 0.8% (95% CI: -1.7% to 3.3%) Virologic Success* *HIV-1 RNA < 50 copies/ml. Wk 24 Virologic Efficacy 0.5 (n = 4) Virologic Failure DRV/COBI/FTC/TAF (n = 763) Boosted PI + FTC/TDF (n = 378) Treatment difference: -0.3% (95% CI: -2.0% to 1.5%) 0.8 (n = 3) No Virologic Data Molina JM, et al. IAS Abstract TUAB0101. Virologic Rebound No PI or NRTI resistance associated mutations noted (n = 2 genotyped for each treatment group) Similar low rates of grade 3/4 AEs, d/c for AEs between treatment groups Significant improvements in hip/spine BMD for DRV/COBI/FTC/TAF vs control Similar egfr by serum creatinine between groups (P =.118); increased egfr by cystatin c with DRV/COBI/ FTC/TAF (P =.026) Slide credit: clinicaloptions.com Pts (%) AMBER: DRV/COBI/FTC/TAF vs DRV/COBI + FTC/TDF for Treatment-Naive Pts Treatment difference: 2.7% (95% CI: -1.6% to 7.1%) Wk 48 Virologic Efficacy Virologic Success* DRV/COBI/FTC/TAF (n = 362) DRV/COBI + FTC/TDF (n = 363) (n = 16) (n = 12) HIV-1 RNA 50 c/ml *Primary endpoint: HIV-1 RNA < 50 c/ml by FDA snapshot. 1 treatment-emergent resistance mutation (M184I/V) observed in DRV/COBI/FTC/TAF arm Similar low rates of grade 3/4 AEs between treatment groups Lower rate of AE-related d/c for DRV/COBI/FTC/TAF vs DRV/COBI + FTC/TDF (1.9% vs 4.4%) Hip/spine BMD changes more favorable with DRV/COBI/FTC/TAF Significantly higher egfr by serum creatinine (P <.0001) and cystatin c (P =.001) with DRV/COBI/FTC/TAF Final Audience Vote Would you recommend switching off the protease inhibitor and switching to an integrase inhibitor? Or stay with current protease inhibitor? (A) I would switch the PI to an INSTI. (B) I would continue the PI. Orkin C, et al. EACS Abstract PS8/2. Reproduced with permission. Slide credit: clinicaloptions.c 7
8 Patient 3 65 year old woman with: chronic kidney disease (egfr = 40 ml/min) severe osteoporosis (DEXA with T-score -3.1 in hip) coronary artery disease (recent exercise treadmill test positive for ischemia) and HTN: takes ASA 81mg QD, metoprolol 25mg QD, and lisinopril 5mg QD Diagnosed with HIV in 2016 (records unavailable) à started on TAF/FTC (Descovy) + dolutegravir (Tivicay) à virally suppressed since then You want to switch to a nucleoside-sparing ART regimen for medical reasons; patient also wants this Audience Preliminary Vote What type of NRTI-sparing regimen would you construct? (A) I would give a 2-drug NRTI-sparing regimen (B) I would give a 3-drug NRTI-sparing regimen Case 3: Susa Coffey Would use a 2-drug NRTI-sparing regimen 8
9 Case 3 switch to NRTI-Sparing 2-drug ART. 65 yo woman with CKD (egfr 40), severe osteopenia, CAD. On stable suppressive TAF/FTC + DTG, needs to switch to a NRTI-sparing regimen. Q1: 2 drugs vs 3 drugs? Q2: does 3TC/FTC count as a NRTI? we can go either way on this A good 2-drug regimen likely to be sufficient; she is an excellent candidate: She has proved her ability to adhere closely to ART Stable viral suppression Likely wildtype virus Case 3 switch to 2-drug regimen. 65 yo woman with CKD (egfr 40), severe osteopenia, CAD. On stable suppressive TAF/FTC + DTG, needs to switch to a NRTI-sparing regimen LOTS of good new data! DTG/RPV DTG + 3TC DTG + DRV/r DRV/r + 3TC HIV-1 RNA <50 c/ml, % Switch to DTG + RPV: SWORD 1/ Virologic outcomes, Week <1 1 0 Virologic Virologic a Adjusted for age success and baseline 3 rd agent. non-response DTG + RPV (n=513) CAR (n=511) 5 4 No virologic data N=1024, viral suppression 12 months, stable ART 6 mos DTG + RPV non-inferior to CAR, incl in subgroups (age, gender, race) VF in 2 in dual arm, 1 w/ K101K/E, resuppressed BMD improved on DTG/RPV after switch from TDF (DEXA substudy) DTG/RPV approved by FDA Nov 2017 (Juluca): switch from stable ART, VS, no VF, no resistance Llibre et al. CROI 2017; Seattle, WA. Abstract 44LB. McComsey G, IAS Switch to DTG + 3TC (and remember the Naive trials- Case 1) Study N Baseline Results Ref LAMIDOL Single arm, prospective, open label DTG/3TC vs DTG mono vs 3-drug RTC ASPIRE DTG/3TC vs current ART; RCT DTG/3TC vs historic control Prosp. open label Single arm, prospective, open label 104 VL <50 x 2 yrs, no R 91 VL <50 x 12 mos, no VF or resistance to 3TC or INI 89 VL <50 on any 3-d ART No VF, no R 183 DTG, 170 DRV, 141 ATV 72 (vs 86 control) VL <50, no VF with INI resistance 203 VL <50 6 mos, median 72 mos Wk 48: VL <50 101/ rebound to 77 c/ml, 1 LTFU, 1 interrupted. No IN resistance, 1 w/ L74V/L. Wk 24: DTG/3TC: 1 VF (low level VL, no resistance) DTG mono: 2 VF with INI R (this arm stopped) Wk 24: VL <50 in 93% vs 91% Wk 48: 91% vs 89% 1 VF in DTG/3TC, no R Up to 2 yrs VF: 3 (DTG), 6 (DRV), 4 (ATV) Wd 96: VL <50 in 97% in both gps Blips in 1 vs 6 VF: 0 (295 pt-yrs of f/u) d/c: 12 Retrospective % VL <50 Median 23 wks: VL <50 97% (82/84) 1 VL=55, 1 VL=239 Metaanalysis of 4 DTG/3TC studies 261 VL <50 VF in 1 DTG/3TC, no mutations Joly V, EACS Blanco JL, EACS Taiwo BO, EACS Borghetti, EACS Tau L, EACS Maggiolo F, EACS 2017; BMC ID DTG/3TC vs DRV/r/3TC vs ATV/r/3TC Retrosp. investigatorselected Hidalgo- Tenorio C, EACS Buzzi M, EACS 9
10 INSTI + PI/r or PI/r + 3TC: Switch(2) and Naïve(1) each INSTI + PI/r N Baseline Results Ref NEAT-001 RAL/DRV-r vs DRV/r/TDF/FTC Naive DTG + DRV/r Switch, single arm DTG + DRV/r Switch, retrosp. PI/r + 3TC N Baseline Results Ref DUAL DRV/r + 3TC vs DRV/r + 2 NRTIs RTC open label switch Metaanalysis of 4 PI/r + 3TC studies ANDES DRV/r + 3TC vs DRV/r + TDF/3TC RTC open label Naive 805 No resistance CD4 < VL <50 x >6 mo on DRV/r + 2 NRTIs, no R TDF/FTC in 75%, ABC/3TC 25% 1051 (525 on dual) 145 Median BL VL 4.6 log, >100,000 in 27% Noninferior 96 wks: VL <5 on 89% vs 93%, incr VF in RAL/DRV if VL >100K or CD4 <200 R: 5 with IN mutations, 1 K65R 27 Suppressed 48 wks: VL <50 in 25/27 (93%) 1 VF, no resistance % with VF Resistance to 1-5 ARV classes or hx VF w/o GT. 17% with DRV RAMS, 11% with INI RAMS 48 weeks: VL <50 in 91% (14 took ARVs BID) No new R mutations Wk 48: VL <50 in 89% vs 93% VF in n=4 vs w/ VL <200, 1 VF at BL, 1 VF during study No R either arm Wk 48 VL <50: PI/3TC noninferior (4% margin); no diffs by gender, HCV, or PI Wk 24: VL <400 in 95% vs 97% On treatment: 100% vs 99% 1 VF in 3-drug arm Raffi F, Lancet Navarro, J. EACS Capetti AF, BMC ID Pulido F, CID, Perez-Molina A, EACS Sued O, IAS Case 3 switch to 2-drug regimen Already on DTG let s keep it Prefer to avoid PIs ØLargest RTC: DTG + RPV ØAccumulation of data DTG + 3TC Case 3: Counterpoint: Annie Luetkemeyer: Too soon for 2 drug therapy here! The #1 goal for her is to maintain virologic suppression! This patient would not have qualified for SWORD, PADDLE, NEAT given her comorbidities DTG + 2 nd drug is one step away from DTG monotherapy Excellent data to support 3 drug regimens, including NRTI-sparing regimens Would stick with a 3-drug NRTI-sparing regimen Fagard IAS 2009, JAIDS 2012; 59(5);489 Tashima AIM 2015; 163(12);
11 Final Audience Vote What type of NRTI-sparing regimen would you construct? (A) I would give a 2-drug NRTI-sparing regimen Acknowledgements Monica Gandhi, MD Oliver Bacon, MD Thank you for participating! (B) I would give a 3-drug NRTI-sparing regimen 11
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches
Switching ARV Regimens: Managing Toxicity and Improving Tolerability; Switches & Class-Sparing Approaches Harry W. Lampiris, MD Chief, Infectious Disease Section, San Francisco VA Medical Center Professor
More informationCROI 2017 Review: Novel ART Strategies
Mountain West AIDS Education and Training Center CROI 2017 Review: Novel ART Strategies Brian R. Wood, MD Assistant Professor of Medicine Medical Director, Mountain West AETC ECHO Telehealth March 2, 2017
More informationCase 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1
MMAH Debate Panel Thursday, December 8, 2016 Case 1 HPI 55 yo man with newly diagnosed HIV initiates care in your clinic. His CD4+ cell count is 600, with HIV VL=90,000 copies/ml. He is asymptomatic at
More informationWhat is the magic number? Clinical perspective
What is the magic number? Clinical perspective Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena UOC Malattie Infettive AOU Senese Outline Regimens with reduced number of drugs Use
More informationCROI 2018 Report Back
CROI 2018 Report Back Monika Roy, MD MAS Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine bayareaaetc.org 1 Disclosures and Conflicts of Interest Nothing to report bayareaaetc.org
More informationDisclosures. Goals/Format. Patient 1 12/8/18. Antiretroviral Therapy Management. Harry Lampiris: None. Gabriel Chamie: None.
Disclosures Antiretroviral Therapy Management Panel Discussion & Debate Medical Management of AIDS & Hepatitis December 6, 2018 Harry Lampiris, MD, 1 Gabriel Chamie, MD, MPH 2 Susa Coffey, MD, 2 and Vivek
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationDebating view on less ART. Strategies under evaluation
Debating view on less ART Strategies under evaluation Andrea De Luca Dipartimento Biotecnologie Mediche Università di Siena Department of Infectious Diseases, Siena University Hospital, Italy Conflicts
More informationState of the ART: Integrase Inhibitors Clinical Data. Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain
State of the ART: Integrase Inhibitors Clinical Data Juan Berenguer Hospital General Universitario Gregorio Marañón (IiSGM) Madrid, Spain Disclosures Consulting fees and honoraria Gilead, Janssen, MSD,
More informationTwo Drug Regimens Pros and Cons. Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany
Two Drug Regimens Pros and Cons Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany HIV Clinical Forum, Moscow, Russia, Friday 23 rd November 2018 Conflict of Interest: JKR
More informationDavid Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone
David Cluck, PharmD, BCPS, AAHIVP Associate Professor of Pharmacy Practice Office 326 Phone 423-439-6245 Email cluckd@etsu.edu Recall newly approved antiretrovirals and their respective place in therapy
More informationAre the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine
Are the current doses of ARV correct Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine Can we lower doses of HIV meds safely? Consensus Panel in Alexandria
More informationReduced drug regimens
Reduced drug regimens Andrea De Luca MD Dipartimento di Biotecnologie Mediche, Università di Siena Department of Internal Medicine, University Hospital, Siena, Italy Conflicts of interest Research grants
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question 12/6/2017
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationCrafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary?
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI s Necessary? Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical
More information11/7/2016. Antiretroviral Therapy Strategies. Learning Objectives. After attending this presentation, participants will be able to:
Antiretroviral Therapy Strategies FORMATTED: 1/14/16 Joel E. Gallant, MD, MPH Medical Director of Specialty Services Southwest CARE Center Santa Fe, New Mexico Adjunct Professor of Medicine The Johns Hopkins
More informationClinical support for reduced drug regimens. David A Cooper The University of New South Wales Sydney, Australia
Clinical support for reduced drug regimens David A Cooper The University of New South Wales Sydney, Australia Clinical support for reduced drug regimens First line optimisation Virological failure New
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors. Pedro Cahn
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Pedro Cahn Disclosures Research Grants: Abbvie-Merck-Richmond-ViiV Advisory boards: Merck-Sandoz-ViiV Switching in Virologically
More informationReduced drug regimens. Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona
Reduced drug regimens Josep M Llibre Infectious Diseases & Fight AIDS Fndn Univ Hosp Germans Trias i Pujol Badalona, Barcelona jmllibre@flsida.org 9th IAS Conference on HIV Science (IAS 2017) 23 26 July
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More informationID Week 2016: HIV Update
Mountain West AIDS Education and Training Center ID Week 2016: HIV Update Robert Harrington, M.D. This presentation is intended for educational use only, and does not in any way constitute medical consultation
More informationMore Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD
More Options, Some Opinions Initial Therapies for HIV Judith S. Currier, MD More Options, Some Opinions: Initial Therapies for HIV Judith S. Currier, MD University of California Los Angeles Los Angeles,
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationDolutegravir-Rilpivirine (Juluca)
Dolutegravir-Rilpivirine (Juluca) David H. Spach, MD Clinical Director, MW AETC Professor of Medicine Division of Infectious Diseases University of Washington Last Updated: November 30, 2017 ANTIRETROVIRAL
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationCase # 1. Case #1 (cont d)
Antiretroviral Therapy Management: Expert Panel Discussion George Beatty Susa Coffey Steve O Brien December 3, 2011 Moderated by Annie Luetkemeyer Case # 1 38 y.o. man, CD4 =350, VL=340K, new to your clinic
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationThe Integrase Inhibitor Drug Class: A Comparative Clinical Review
The Integrase Inhibitor Drug Class: A Comparative Clinical Review Ian Frank Professor of Medicine University of Pennsylvania Philadelphia, PA USA franki@pennmedicine.upenn.edu Disclosure Gilead, ViiV/GlaxoSmithKline:
More informationDidactic Series. CROI 2014 Update. March 27, 2014
Didactic Series CROI 2014 Update Christian Ramers, MD, MPH Family Health Centers of San Diego Ciaccio Memorial Clinic Jacqueline Peterson Tulsky, MD UCSF Positive Health Program at SFGH Medical Director,
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationHIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London
HIV Treatment Update Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London Guidelines Nuke sparing Nukes Efavirenz placement as the gold standard ARV Role
More information2-Drug regimens in HIV Anton Pozniak MD FRCP
2-Drug regimens in HIV Anton Pozniak MD FRCP Advantages Cost Dual Therapy Toxicities of Nukes CV risk, bone, renal disease Smaller STRs Keep drugs for later etc. Dual Therapy-Talking Points - What are
More informationState of the art of ART
No disclosures State of the art of ART Medical Management of AIDS December 7, 2017 Monica Gandhi MD, MPH Professor of Medicine, Division of HIV, Infectious Diseases and Global Medicine, UCSF Medical Director,
More informationAntiretroviral Therapy: Panel Discussion
disclosures Antiretroviral Therapy: Panel Discussion Medical Management of HIV December 9, 217 Panelists: Harry Lampiris, MD; Annie Luetkemeyer, MD; Carina Marquez, MD Moderator: Oliver Bacon, MD none
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationSimplified regimens: Pros and Cons
Rio de Janeiro, 2018 Simplified regimens: Pros and Cons Pedro Cahn Treatment Strategies: A long way Monotherapy Dual therapy STIs Triple therapy Non daily regimens Simplification Mega HAART Long Acting/Extended
More informationThe next generation of ART regimens
The next generation of ART regimens By Gary Maartens Presented by Dirk Hagemeister Division of Clinical Pharmacology UNIVERSITY OF CAPE TOWN IYUNIVESITHI YASEKAPA UNIVERSITEIT VAN KAAPSTAD Current state
More informationDisclosures (last 12 months)
HIV Research What s in the Pipeline? Samir K. Gupta, MD, MS Division of Infectious Diseases Indiana University School of Medicine Disclosures (last 12 months) Independent research grant funding by NIH/NHLBI,
More informationReport Back: HIV Treatment Updates
Report Back: HIV Treatment Updates Catherine Koss, MD Assistant Professor Division of HIV, Infectious Diseases, and Global Medicine Zuckerberg San Francisco General Hospital University of California, San
More informationTreating HIV: When the Guidelines Don t Fit. Joel Gallant, MD, MPH. Southwest CARE Center Santa Fe, New Mexico
Treating HIV: When the Guidelines Don t Fit Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, New Mexico Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures
More informationCases from the Clinic(ians): Case-Based Panel Discussion
Cases from the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine The University of Alabama at Birmingham EDITED: 03-12-14 Learning Objectives After attending this presentation,
More informationACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals
ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals ACTHIV 2018: A State-of-the-Science Conference for Frontline Health Professionals Are You Ready? New Drugs Are on the Way!
More informationHIV 101. Applications of Antiretroviral Therapy
HIV 101. Applications of Antiretroviral Therapy Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama at Birmingham Birmingham,
More informationINDUCTION/MAINTENANCE Clinical Case
INDUCTION/MAINTENANCE Clinical Case Dr. Jose R Arribas @jrarribas INDUCTION/MAINTENANCE (more or less) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD
More informationInvestigational Approaches to Antiretroviral Therapy
Investigational Approaches to Antiretroviral Therapy Rajesh T. Gandhi, MD Massachusetts General Hospital Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending
More informationHIV Clinical Management: Antiretroviral Therapy and Drug Resistance
HIV Clinical Management: Antiretroviral Therapy and Drug Resistance Judith S. Currier, MD, MSc Professor of Medicine University of California, Los Angeles Disclosures: Research Grant from Theratechnologies
More informationDRUGS IN PIPELINE. Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015
DRUGS IN PIPELINE Pr JC YOMBI UCL-AIDS REFERENCE CENTRE BREACH Sept 27, 2015 N(t)RTI The Development of TAF TAF Delivers the High Potency of TDF While Minimizing Off- Target Kidney and Bone Side Effects
More informationAntiretroviral Therapy: What to Start
FLOWED: 05-14-2015 Chicago, IL: May 18, 2015 Antiretroviral Therapy: What to Start Eric S. Daar, MD Professor of Medicine David Geffen School of Medicine University of California Los Angeles Los Angeles,
More informationQué anuncian los nuevos trials?
Qué anuncian los nuevos trials? XVII Curso Nacional VIH/SIDA Sociedad Chilena de Infectología Agosto 2014 Dr. Carlos Beltrán Hospital Barros Luco Trudeau Universidad de Santiago Grupo SidaChile El presente
More informationTerapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales
Terapia del paciente naive con un régimen de Inhibidor de la proteasa Dr. Jose R Arribas IX Curso de avances en Infección VIH y hepatitis virales clinicaloptions.com/hiv Eficacia en Ensayos Clínicos pivotales
More informationThe Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases
De afbeelding kan niet worden weergegeven. The Use of Integrase Inhibitors In Latin America: From Guidelines to the Real World Ernesto Martínez B., MD Internal Medicine, Infectious Diseases DISCLOSURE
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationAbstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo
WEEK 8 RESULTS OF AMBER: A PHASE 3, RANDOMISED, DOUBLE-BLIND TRIAL IN ANTIRETROVIRAL TREATMENT (ART)-NAÏVE HIV--INFECTED ADULTS TO EVALUATE THE EFFICACY AND SAFETY OF THE ONCE-DAILY, SINGLE-TABLET REGIMEN
More informationRajesh T. Gandhi, M.D.
HIV Treatment Guidelines: 2010 Rajesh T. Gandhi, M.D. Case 29 yo M with 8 weeks of cough and fever. Diagnosed with smear-positive pulmonary TB. HIV-1 antibody positive. CD4 count 361. HIV-1 RNA 23,000
More informationViiV Healthcare investor & analyst update
ViiV Healthcare investor & analyst update 15 February 2017 David Redfern, GSK Chief Strategy Officer and Chairman, ViiV Healthcare Dr. Dominique Limet, Chief Executive Officer, ViiV Healthcare Dr. John
More informationTerapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R
Terapia Antirretroviral en la Infección por el VIH (problemas, retos y soluciones) Dr. Jose R Arribas @jrarribas Disclosures Speaker s Bureau: Gilead Board Member/Advisory Panel: MSD, Gilead, Janssen,
More informationPanelists Melanie Thompson Jeffrey Lennox Wendy Armstrong Jonathan Li
Slide 1 of 51 Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University
More informationHIV Update Four Corners Conference Linda Gorgos, MD, MSc, FIDSA Southwest Care Center Santa Fe, NM
HIV Update Four Corners Conference 2018 Linda Gorgos, MD, MSc, FIDSA Southwest Care Center Santa Fe, NM Disclosures Our clinic receives funding for clinical trials from Gilead, Abbvie, Janssen, Merck,
More informationPotential Issues in Treating HIV/HCV co-infection with new HCV antivirals
State of the Art in Hepatitis C Virus Infection in HIV/HCV-Coinfected Patients FORMATTED: 11/17/15 David L. Wyles, MD Associate Professor of Medicine University of California San Diego San Diego, California
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationPretreatment drug resistance and new treatment paradigms in firstline
Michelle Moorhouse October 2018 27 th International Workshop on HIV Drug Resistance and Treatment Strategies Pretreatment drug resistance and new treatment paradigms in firstline ART Disclosures/disclaimers
More informationProfessor José Arribas
19 th Annual Conference of the British HIV Association (BHIVA) Professor José Arribas Hospital La Paz, Madrid, Spain 16-19 April 2013, Manchester Central Convention Complex Can we live without nucleosides?
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More information2/16/2017. Management and Prevention of HIV Infection: Case Discussion. Case 1. Case 1
Management and Prevention of HIV Infection: Case Discussion Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA Grant
More informationAntiretroviral Treatment 2014
Activity Code FM285 Antiretroviral Treatment 2014 Rajesh Gandhi, MD Masssachusetts General Hospital Disclosures: Educational grants to my institution from Janssen, Viiv, Abbott Learning Objectives Upon
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationHIV Update. On The Cutting Edge A Chronic Disease. Rhett M Shirley, MD
HIV Update On The Cutting Edge A Chronic Disease Rhett M Shirley, MD CDC Mid-point life expectancy estimates at age 20 years in three calendar periods, overall and by sociodemographic characteristics,
More informationTDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia
TDF containing ART: Efficacy and Safety Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia 1 Indications Treatment of HIV-1 in combination with other antiretroviral
More informationTim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC
Tim Horn Deputy Executive Director, HIV & HCV Programs Treatment Action Group NASTAD Prevention and Care Technical Assistance Meeting Washington, DC July 19, 2017 Pipeline is robust! Several drugs, coformulations,
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationUpdates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017
Mountain West AIDS Education and Training Center Updates to the HHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV Updated October 17, 2017 26 October 2017 Hillary
More informationHIV Update Allegra CPD Day Program Port Elizabeth Dr L E Nojoko
HIV Update 2014 Allegra CPD Day Program Port Elizabeth 12-02-2014 Dr L E Nojoko Global estimates for adults and children 2011 People living with HIV 34.0 million [31.4 million 35.9 million] New HIV infections
More informationManagement of patients with antiretroviral treatment failure: guidelines comparison
The editorial staff Management of patients with antiretroviral treatment failure: guidelines comparison A change of therapy should be considered for patients if they experience sustained rebound in viral
More informationAcquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Acquired INSTI Resistance Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting honoraria, speaker
More informationOptimizing Clinical Utility of Integrase Inhibitors. Anton Pozniak MD FRCP
Optimizing Clinical Utility of Integrase Inhibitors Anton Pozniak MD FRCP INSTIs-Characteristics Rapid viral load decline Low rates resistance/ Transmitted Resistance Less chance of side effects Less pills,
More informationSwitching antiretroviral therapy to safer strategies based on integrase inhibitors
Switching antiretroviral therapy to safer strategies based on integrase inhibitors Dr Paddy Mallon UCD HIV Molecular Research Group UCD School of Medicine paddy.mallon@ucd.ie UCD School of Medicine & Medical
More informationGenotypic Resistance Testing in Routine Care in South Africa:
Genotypic Resistance Testing in Routine Care in South Africa: Is the Juice Worth the Squeeze? Mark Siedner Africa Health Research Institute Harvard Medical School Conflicts of Interest^* No financial conflicts
More informationARVs in Development: Where do they fit?
The picture can't be displayed. ARVs in Development: Where do they fit? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker
More informationWHEN TO START? CROI 2015: Focus on ART
CROI 215: Focus on ART FORMATTED: 4-1-15 Washington, DC: May 13, 215 Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine Chief, Division of Infectious Diseases Weill Cornell Medical
More informationWhat is the virological support for reduced drug regimens?
What is the virological support for reduced drug regimens? Pr Anne-Genevieve Marcelin Pitié-Salpêtrière Hospital UMR 1136 University Pierre et Marie Curie Paris, France Disclosure of Personal and Commercial
More informationAntiretroviral Therapy in 2016
Antiretroviral Therapy in 2016 Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM University of New Mexico School of Medicine Johns Hopkins University School of Medicine Disclosures Consulting, Advisory
More informationDidactic Series. Switching Regimens in the Setting of Virologic Suppression
Didactic Series Switching Regimens in the Setting of Virologic Suppression Craig Ballard, PharmD, AAHIVP UC San Diego Health Owen Clinic June 14 th, 2018 1 Learning Objectives 1) Describe DHHS guidelines
More informationCROI 2017 Highlights What s New in Antiretrovirals (Part 2)
Mountain West AIDS Education and Training Center CROI 2017 Highlights What s New in Antiretrovirals (Part 2) Ann Collier, MD This presentation is intended for educational use only, and does not in any
More informationHistory (August 2010) Therapy for Experienced Patients. History (September 2010) History (November 2010) 12/2/11
(August 2010) Therapy for Experienced Patients Hiroyu Hatano, MD, MHS Assistant Professor of Medicine University of California San Francisco Medical Management of AIDS December 2011 42M HIV (CD4=450, VL=6250,
More informationSimplifying Antiretroviral Therapy Regimens: It s not so simple
Simplifying Antiretroviral Therapy Regimens: It s not so simple Jonathan Colasanti, MD, MSPH Division of Infectious Diseases Emory University School of Medicine Disclosures No Financial Disclosures Parts
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationStarting and Switching ART: 2016
Starting and Switching ART: 2016 Luke Jerram Rajesh T. Gandhi, M.D. Massachusetts General Hospital Harvard Medical School Disclosures: grant support from EBSCO, Gilead, Merck, Viiv Thanks to Henry Sunpath,
More informationHIV Treatment Update
HIV Treatment Update Joel Gallant, MD, MPH Southwest CARE Center Santa Fe, NM Johns Hopkins University School of Medicine University of New Mexico School of Medicine Disclosures Consulting, Advisory Boards,
More informationThe Dawn of the TLD Era
The Dawn of the TLD Era 20th September 2018 Mark Siedner Africa Health Research Institute Harvard Medical School Outline: A Primer on Dolutegravir Do we really need more HIV drugs? The case for a new first-line
More informationTreating HIV in 2018 Interactive Cases From the Clinic(ians)
Slide 1 of 51 Treating HIV in 2018 Interactive Cases From the Clinic(ians) Michael S. Saag, MD Professor of Medicine Associate Dean for Global Health Jim Straley Chair in AIDS Research University of Alabama
More informationINTERGRASE INHIBITORS- WHAT S NEW?
INTERGRASE INHIBITORS- WHAT S NEW? Professor Margaret Johnson Royal Free London Foundation Trust October 2018 Targeting the HIV life-cycle NEW HIV VIRON MATURATION CO-RECEPTOR BINDING FUSION BUDDING CD4
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationD:A:D: Cumulative Exposure to DRV/r Increase MI Risk
D:A:D: Cumulative Exposure to DRV/r Increase MI Risk 20.0-15.0-10.0-5.0-4.0-3.0-2.0-1.0- Unadjusted CVD rate ratios per 5 years additional exposure: ATV/r 1.25 [1.10-1.43] and DRV/r 1.93 [1.63-2.28] Adjusted*
More informationDrug toxicities: Safest PIs. Michelle Moorhouse 14 Apr 2016
Drug toxicities: Safest PIs Michelle Moorhouse 14 Apr 2016 Impact of PIs on AIDS mortality CDC.gov. Epidemiology of HIV infection. Evolution of PIs http://www.clinicaloptions.com/hiv/treatment%20updates/boosted%20pis/interactive%20virtual%20presentation/slideset.aspx
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More information